Effect of eveing primrose oil in ripening of cervix before of gynecologic surgeries

Primrose oil gel capsule on the Ease of Cervical Ripening Before Operative Hysteroscopy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140525017827N12

Enrollment

100

Registered

2021-08-23

Start date

2021-08-23

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical preparation before hysteroscopic surgery. Polyp of corpus uteri

Interventions

Intervention 1: Intervention group: 2 capsules of evening primrose 1000 mg (made by webber naturals Canada with confirmation code 1505809997164877771629, UID: 15210012004109455083 and GTN: 06260084724

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Candidate for hysteroscopy Aged 18-50 years No pregnancy Consent to participate in the study Women who do not have a history of normal delivery or cervical manipulation Spinal anesthesia nulliparity

Exclusion criteria

Exclusion criteria: Those who had a contraindication to PGs (history of severe asthma, glaucoma, preexisting cardiac disease, hypertension, or renal failure, bleeding disorders or consuming medications that inhibit blood clotting, Patients with a history of schizophrenia who take phenothiazines patients with epilepsy and seizure Significant uterovaginal prolapse precluding the administration of vaginal tablets. History of cervical incompetence Mullerian anomaly or a history of a cervical cone biopsy, General anesthesia BMI>35

Design outcomes

Primary

Measure	Time frame
Size of first input hegar dilator. Timepoint: At the beginning of the study and immediately after the hysteroscopy (4-6 hours after taking the drug). Method of measurement: Measurement of cervical dilatation: Hegar dilator.	—

Secondary

Measure	Time frame
Complications of the drug before, during and after hysteroscopy. Timepoint: After prescribing the drug (4-6 hours later) and immediately before the hysteroscopic surgery and during the operation. Method of measurement: Clinical observation.;Cervical consistency after drug administration. Timepoint: After prescribing the drug (4-6 hours later) and immediately before the hysteroscopic surgery and during the operation. Method of measurement: Check the consistency of the cervix with a finger examination, Hegar Dilator.;Duration of cervical dilatation. Timepoint: After prescribing the drug (4-6 hours later) and immediately before the hysteroscopic surgery and during the operation. Method of measurement: Timing.;The total duration of surgery. Timepoint: During the operation. Method of measurement: Timing.	—

Measure

Time frame

Complications of the drug before, during and after hysteroscopy. Timepoint: After prescribing the drug (4-6 hours later) and immediately before the hysteroscopic surgery and during the operation. Method of measurement: Clinical observation.;Cervical consistency after drug administration. Timepoint: After prescribing the drug (4-6 hours later) and immediately before the hysteroscopic surgery and during the operation. Method of measurement: Check the consistency of the cervix with a finger examination, Hegar Dilator.;Duration of cervical dilatation. Timepoint: After prescribing the drug (4-6 hours later) and immediately before the hysteroscopic surgery and during the operation. Method of measurement: Timing.;The total duration of surgery. Timepoint: During the operation. Method of measurement: Timing.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactOmolbanin Hasani

Shiraz University of Medical Sciences

banin.hassani5349@gmail.com+98 71 3648 9830

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026